158 related articles for article (PubMed ID: 10194118)
1. The relevance of plasminogen activator inhibitor 1 (PAI-1) as a marker for the diagnosis of hepatic veno-occlusive disease in patients after bone marrow transplantation.
Salat C; Holler E; Kolb HJ; Pihusch R; Reinhardt B; Penovici M; Ledderose G; Hiller E
Leuk Lymphoma; 1999 Mar; 33(1-2):25-32. PubMed ID: 10194118
[TBL] [Abstract][Full Text] [Related]
2. Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation.
Salat C; Holler E; Kolb HJ; Reinhardt B; Pihusch R; Wilmanns W; Hiller E
Blood; 1997 Mar; 89(6):2184-8. PubMed ID: 9058743
[TBL] [Abstract][Full Text] [Related]
3. Role of plasminogen activator inhibitor-1 (PAI-1) levels in the diagnosis of BMT-associated hepatic veno-occlusive disease and monitoring of subsequent therapy with defibrotide (DF).
Kaleelrahman M; Eaton JD; Leeming D; Bowyer K; Taberner D; Chang J; Scarffe JH; Chopra R
Hematology; 2003 Apr; 8(2):91-5. PubMed ID: 12745658
[TBL] [Abstract][Full Text] [Related]
4. Parameters of the fibrinolytic system in patients undergoing BMT: elevation of PAI-1 in veno-occlusive disease.
Salat C; Holler E; Reinhardt B; Kolb HJ; Seeber B; Ledderose G; Mittermueller J; Duell T; Wilmanns W; Hiller E
Bone Marrow Transplant; 1994 Nov; 14(5):747-50. PubMed ID: 7889007
[TBL] [Abstract][Full Text] [Related]
5. Plasminogen activator inhibitor-1 is an independent diagnostic marker as well as severity predictor of hepatic veno-occlusive disease after allogeneic bone marrow transplantation in adults conditioned with busulphan and cyclophosphamide.
Lee JH; Lee KH; Lee JH; Kim S; Seol M; Park CJ; Chi HS; Kang W; Kim ST; Kim WK; Lee JS
Br J Haematol; 2002 Sep; 118(4):1087-94. PubMed ID: 12199790
[TBL] [Abstract][Full Text] [Related]
6. Veno-occlusive disease of the liver after allogeneic bone marrow transplantation for severe aplastic anemia.
Lee JH; Lee KH; Choi SJ; Min YJ; Kim JG; Kim S; Lee JS; Kim SH; Park CJ; Chi HS; Kim WK
Bone Marrow Transplant; 2000 Sep; 26(6):657-62. PubMed ID: 11041568
[TBL] [Abstract][Full Text] [Related]
7. Diagnosis of hepatic veno-occlusive disease by plasminogen activator inhibitor-1 plasma antigen levels: a prospective analysis in 350 allogeneic hematopoietic stem cell recipients.
Pihusch M; Wegner H; Goehring P; Salat C; Pihusch V; Hiller E; Andreesen R; Kolb HJ; Holler E; Pihusch R
Transplantation; 2005 Nov; 80(10):1376-82. PubMed ID: 16340778
[TBL] [Abstract][Full Text] [Related]
8. Changes in hemostatic parameters in hepatic veno-occlusive disease following bone marrow transplantation.
Park YD; Yasui M; Yoshimoto T; Chayama K; Shimono T; Okamura T; Inoue M; Yumura-Yagi K; Kawa-Ha K
Bone Marrow Transplant; 1997 May; 19(9):915-20. PubMed ID: 9156266
[TBL] [Abstract][Full Text] [Related]
9. Laboratory markers of veno-occlusive disease in the course of bone marrow and subsequent liver transplantation.
Salat C; Holler E; Wolf C; Kolb HJ; Reinhardt B; Pihusch R; Krämling HJ; Heinemann V; Haller M; Hiller E
Bone Marrow Transplant; 1997 Mar; 19(5):487-90. PubMed ID: 9052916
[TBL] [Abstract][Full Text] [Related]
10. Endothelial dysfunction after bone marrow transplantation: increase of soluble thrombomodulin and PAI-1 in patients with multiple transplant-related complications.
Nürnberger W; Michelmann I; Burdach S; Göbel U
Ann Hematol; 1998 Feb; 76(2):61-5. PubMed ID: 9540759
[TBL] [Abstract][Full Text] [Related]
11. Role of fibrinolytic and clotting parameters in the diagnosis of liver veno-occlusive disease after hematopoietic stem cell transplantation in a pediatric population.
Sartori MT; Spiezia L; Cesaro S; Messina C; Paris M; Pillon M; Saggiorato G; Pagnan A; Girolami A; Zanesco L; Cella G
Thromb Haemost; 2005 Apr; 93(4):682-9. PubMed ID: 15841312
[TBL] [Abstract][Full Text] [Related]
12. Veno-occlusive disease (VOD) of the liver in Korean patients following allogeneic bone marrow transplantation (BMT): efficacy of recombinant human tissue plasminogen activator (rt-PA) treatment.
Lee JH; Lee KH; Choi JS; Zang DY; Kim SB; Kim SW; Suh C; Lee JS; Kim WK; Lee YS; Kim SH
J Korean Med Sci; 1996 Apr; 11(2):118-26. PubMed ID: 8835758
[TBL] [Abstract][Full Text] [Related]
13. PAI-1 and protein C as early markers of veno-occlusive disease in patients treated for Wilms tumor.
Cesaro S; Mauro M; Sattin G; Sartori MT; Saggiorato G; Paratella A; Tridello G; Bisogno G
Pediatr Blood Cancer; 2019 Jul; 66(7):e27695. PubMed ID: 30865371
[TBL] [Abstract][Full Text] [Related]
14. Monitoring of veno-occlusive disease after bone-marrow transplantation by serum aminopropeptide of type III procollagen.
Salat C; Holler E; Kolb HJ; Hiller E
Lancet; 1993 Oct; 342(8878):1062. PubMed ID: 8105301
[No Abstract] [Full Text] [Related]
15. Hepatic veno-occlusive disease--liver toxicity syndrome after bone marrow transplantation.
Shulman HM; Hinterberger W
Bone Marrow Transplant; 1992 Sep; 10(3):197-214. PubMed ID: 1422475
[TBL] [Abstract][Full Text] [Related]
16. BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation.
Dignan FL; Wynn RF; Hadzic N; Karani J; Quaglia A; Pagliuca A; Veys P; Potter MN; ;
Br J Haematol; 2013 Nov; 163(4):444-57. PubMed ID: 24102514
[TBL] [Abstract][Full Text] [Related]
17. [Hypercoagulability in patients with veno-occlusive disease after bone marrow transplantation].
Salat C; Holler E; Reinhardt B; Kolb HJ; Pihusch R; Neumeister P; Hiller E
Med Klin (Munich); 1994 May; 89(5):245-7. PubMed ID: 8052177
[TBL] [Abstract][Full Text] [Related]
18. Veno-occlusive disease of the liver after blood and marrow transplantation: analysis of pre- and post-transplant risk factors associated with severity and results of therapy with tissue plasminogen activator.
Litzow MR; Repoussis PD; Schroeder G; Schembri-Wismayer D; Batts KP; Anderson PM; Arndt CA; Chen MG; Gastineau DA; Gertz MA; Inwards DJ; Lacy MQ; Tefferi A; Noël P; Solberg LA; Letendre L; Hoagland HC
Leuk Lymphoma; 2002 Nov; 43(11):2099-107. PubMed ID: 12533034
[TBL] [Abstract][Full Text] [Related]
19. Serum procollagen type III is an early and sensitive marker for veno-occlusive disease of the liver in children undergoing bone marrow transplantation.
Heikinheimo M; Halila R; Fasth A
Blood; 1994 May; 83(10):3036-40. PubMed ID: 8180401
[TBL] [Abstract][Full Text] [Related]
20. Tissue plasminogen activator (tPA) as therapy for hepatotoxicity following bone marrow transplantation.
Schriber J; Milk B; Shaw D; Christiansen N; Baer M; Slack J; Tezcan H; Wetzler M; Herzig G
Bone Marrow Transplant; 1999 Dec; 24(12):1311-4. PubMed ID: 10627640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
